Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Genscript Biotech Corporation

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

COMPLETION OF THE DISCLOSEABLE TRANSACTION IN RELATION TO THE SHARE TRANSFERS OF PROBIO CAYMAN FROM THE OFFSHORE TRANSFERORS

Reference is made to the announcement of Genscript Biotech Corporation (the "**Company**") dated 24 November 2026 in relation to, among others, the Share Transfers (the "**Announcement**"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board hereby announces that all the conditions to the closings under the Share Transfer Agreements with the Offshore Transferors have been fulfilled and the closings of the relevant Share Transfers took place on 25 November 2026 (the "**Completion**"). Pursuant to the relevant Share Transfer Agreements, the Company acquired an aggregate of 102,857,135 Series C Preferred Shares of ProBio Cayman from the Offshore Transferors for an aggregate consideration of approximately US$101.3 million.

The Share Transfers involving the Onshore Transferors have not yet been completed as at the date of this announcement, as the settlement of the consideration payable to the Onshore Transferors is subject to the obtaining of the relevant ODI Approvals. The Company will make further announcement(s) in relation to the completion of the remaining Share Transfers as and when appropriate.

Immediately before Completion, the Company held, directly and indirectly, an aggregate of 1,908,917,606 shares in ProBio Cayman, representing approximately 85.09% of the issued share capital of ProBio Cayman. Immediately following Completion, the Company's aggregate direct and indirect shareholding in ProBio Cayman increased to 2,011,774,741 shares, representing approximately 89.68% of the issued share capital of ProBio Cayman, assuming that none of the ESOP Shares have been allotted or issued.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 25 November 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng ("**Mr. Robin Meng**"), Dr. Fangliang Zhang ("**Dr. Frank Zhang**"), Dr. Li Zhu and Ms. Ye Wang ("**Ms. Sally Wang**"); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung ("**Mr. Andy Cheung**"), Mr. Jiuan Pan ("**Mr. Ethan Pan**"), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi ("**Dr. Victor Shi**").*